Product logins

Find logins to all Clarivate products below.


Cardiac Rhythm Management Devices | Market Insights | US | 2024

The US market for cardiac rhythm management devices will grow through 2032, with trends varying by device segment. The COVID19 global pandemic had a negative impact on some CRM procedure volumes in 2020, followed by a period of recovery. Growth in 
market revenue will be driven by increasing adoption of premium-priced devices such as leadless pacemakers and S-ICDs. However, 
increasing competition in the leadless pacemaker and S-ICD markets will put downward pressure on prices and consequently limit 
growth to some extent.
This Medtech 360 Report provides comprehensive data and analysis on the state of the US cardiac rhythm management device 
market from 2019 through 2032.

Related Medtech Insights Reports

Report
Cardiac Rhythm Management Devices – Market Insights – Japan
The Japanese CRM device market will grow over the forecast period. The introduction of novel products—such as the Aurora EV-ICD and dual-chamber leadless pacemakers—and favorable reimbursement…
Report
Cardiac Rhythm Management Devices – Market Insights – Asia Pacific (Supplemental)
The Asia Pacific CRM device market will experience modest growth over the forecast period, driven primarily by the increasing volume of ICM procedures and the adoption of premium-priced devices,…
Report
Cardiac Rhythm Management Devices – Market Insights – Europe (Supplemental)
The European CRM device market will continue to grow modestly over the forecast period, driven primarily by rising ICM procedure volumes, the introduction of dual-chamber leadless pacemakers, and…
Report
Cardiac Rhythm Management Devices – Market Insights – Europe
The European CRM device market will continue to grow modestly over the forecast period, driven primarily by rising ICM procedure volumes, the introduction of dual-chamber leadless pacemakers, and…
Report
Cardiac Rhythm Management Devices | Market Insights | Europe | 2024
The European CRM device market will continue to experience modest growth through 2032, primarily due to increasing adoption of premium-priced devices such as leadless pacemakers and S-ICDs…